Pelthos Therapeutics Inc. (PTHS)
2025-06-30 | ||||
|---|---|---|---|---|
| Provision for income taxes | - | |||
| Research and development | 514,814 | |||
| Professional fees | 1,605,525 | |||
| General and administrative expenses | 1,110,084 | |||
| Total operating expenses | 3,230,423 | |||
| Net loss from operations | -3,230,423 | |||
| Interest income | - | |||
| Interest expense | 218,516 | |||
| Total other expense | -218,516 | |||
| Net loss before provision for income taxes | -3,448,939 | |||
| Net loss | -3,448,939 | |||
| Net loss per common share - basic | -5.38 | |||
| Net loss per common share - diluted | -5.38 | |||
| Weighted average number of common shares outstanding during the period - basic | 640,518 | |||
| Weighted average number of common shares outstanding during the period - diluted | 640,518 | |||